Viewing Study NCT07227402

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 3:45 AM
Ignite Modification Date: 2026-02-22 @ 12:53 AM
Study NCT ID: NCT07227402
Status: RECRUITING
Last Update Posted: 2025-12-19
First Post: 2025-11-07
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Sponsor: Merck Sharp & Dohme LLC
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Renal Cell Carcinoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Carcinoma View
None Renal cell View
None Belzutifan View
None Zanzalintinib View